Healthcare

Botanix Pharmaceuticals (ASX:BOT) is a commercial-stage dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. The company is working to expand commercial adoption of Sofdra following its transition from clinical development into product sales.

In late April 2026 Syntara reported that a Type C meeting with the FDA had supported the design of a Phase 2b study of amsulostat in myelofibrosis, described by the company as a roughly 100-patient, placebo-controlled trial. Management framed the feedback as positioning the …

On 27 July 2026 SomnoMed released a preliminary, unaudited FY26 update. Revenue was expected to come in at A$114 million to A$115 million, falling short of its prior guidance range of A$119 million to A$126 million. The company attributed the shortfall to weaker European …

In aBusinessupdate released on 31 July 2026, Radiopharm reported a quarter-end cash balance of about 4.1 million dollars, down steeply from around 19.2 million dollars in the prior quarter after operating cash outflows of roughly 15 million dollars. To replenish its reserves, the company …

The standout recent event was the release of Phase II data from the company's TRIPP-FFX study, presented at the ESMO Gastrointestinal Cancers Congress on 6 July 2026. The study combined the OncoSil device with FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer. …

On 30 July 2026 Paradigm reported that its Phase 3 knee osteoarthritis trial, known as PARA_OA_012, had completed enrolment. The company recruited 538 participants, above its original target of 466, across 65 clinical sites spanning Australia, the United States, Hong Kong and Moldova.

Amplia Therapeutics (ASX:ATX) is expanding the development pathway for narmafotinib, its targeted cancer drug candidate, through a new lung cancer collaboration while continuing its pancreatic cancer program. The clinical-stage biotechnology company is evaluating whether its FAK inhibitor can improve outcomes when combined with other …